Mediwelcome Healthcare Management & Technology (2159) Fundamentals 2026 — P/E 48.4x, Revenue Analysis | SniperIQ

.62 on the HKSE. This SniperIQ fundamentals page covers Mediwelcome Healthcare Management & Technology's valuation (P/E 48.4x, P/B 3.3x), profitability (net margin 2.1%), revenue (¥468M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Mediwelcome Healthcare Management & Technology's market cap?

Mediwelcome Healthcare Management & Technology (2159) has a market capitalization of approximately HK$440M, trading at HK

.62 on the HKSE. Market cap moves with the live share price.

What is Mediwelcome Healthcare Management & Technology's P/E ratio?

Mediwelcome Healthcare Management & Technology's trailing twelve-month P/E ratio is 48.4x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Mediwelcome Healthcare Management & Technology?

Mediwelcome Healthcare Management & Technology runs a net profit margin of 2.1%, a gross margin of 20.2%, and an operating margin of 0.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Mediwelcome Healthcare Management & Technology generate?

Mediwelcome Healthcare Management & Technology reported revenue of ¥468M for fiscal year 2025, with net income of ¥10M and earnings per share (EPS) of 0.0438. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Mediwelcome Healthcare Management & Technology pay a dividend?

Mediwelcome Healthcare Management & Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Mediwelcome Healthcare Management & Technology financially healthy?

Mediwelcome Healthcare Management & Technology carries a debt-to-equity ratio of 0.49x and a current ratio of 1.89x, with a market beta of -0.27. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Mediwelcome Healthcare Management & Technology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mediwelcome Healthcare Management & Technology (2159) the key facts are: market cap HK$440M, P/E 48.4x, revenue ¥468M, 52-week range 1.06-2.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.